Mabwell’s subsidiary T-mab enters into an agreement with Qilu Pharma for Albipagrastim alfa for injection: Shanghai Monday, June 30, 2025, 15:00 Hrs [IST] Mabwell, an innovative ...

US biotech Arbutus Biopharma (Nasdaq: ABUS) has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

Warminster-based Arbutus Biopharma has ended a 4-year licensing deal worth up to $285 million with Qilu Pharmaceuticals, a ...

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it has reacquired full global rights to its lead RNAi ...

A Bucks County biotech firm and a Chinese pharmaceutical company have ended a licensing deal valued at up to $285 million.

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. | Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the ...

Vital Statistics:Year Founded: 1988Number of Employees: 1600Number of Facilities: 12 Who We Are:PLD Pharma Services focuses on the development, manufacturing and packing of small molecule, liquid and ...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan ...

COLUMBIA, S.C. (WIS) - A pharmaceutical manufacturer is growing their operations in Richland County. Ritedose, a company specializing in Blow-Fill-Seal technology, opened a 225,000-square-foot ...